guide to the TNM/pTNM classification of malignant tumours, 3rd edition. Berlin-Heidelberg-New York: Springer, 1990 . (7) Ten  established astrocytic tumor cell lines,  SW1088, SW1783, Hs683, H4, U87,  U118, U138, U373, T98G , and A172, were studied. The effects of added gastrin (at 0.01, 0.1, and 1 \xM) and the gastrin/CCK antagonists L-365,260, CI-988, L-364,718, and JMV 234 (each at 0.01, 0.1, and 1 \iM) on the cellular proliferation rates of the 10 cell lines were indirectly measured by use of the colorimetric tetrazolium assay. The influence of gastrin (at 0.01 \iM) on the cellular proliferation of primary cultures from nine freshly explanted astrocytic tumors was assessed by means of tritiated thymidine uptake and autoradiography. Results: At specific concentrations, added gastrin increased the cellular proliferation of three established astrocytic cell lines (A172, Hs683, and SW1088), decreased it in two (U373 and T98G), and was without effect on the remaining five. Gastrin decreased cellular proliferation in one primary astrocytic tumor cell culture, stimulated it in five, and had no apparent effect in the remaining three. L-365,260, a CCK receptor B antagonist used at 0.01 \iM, increased cellular proliferation in seven cell lines (A172, H4, Hs683, SW1783, T98G, U118, and U138), decreased it in one (U87), and had no effect in the remaining two. CI-988, another CCK receptor B antagonist used at 0.01 \iM, inhibited cellular proliferation in five cell lines (A172, H4, SW1783, U373, and U87), stimulated it in two (T98G and U138), and had no effect in three. The Malignant astrocytic tumors, which include anaplastic astrocytomas and glioblastomas, represent one of the most lethal forms of cancer in adults. Most of these tumors are biologically heterogeneous (1,2) and are characterized by their infiltrating and diffuse growth into normal brain areas (3). These features contribute to the poor therapeutic response rates among patients with these tumors (2, 4) .
New treatment strategies that involve gene therapy (5) and inhibition of protein kinase C (<5) have recently attracted attention, but these therapies are still experimental. Therapies that are based on the modification of the biologic effects of hormone and/or growth factors hold promise and may be applicable for certain astrocytic tumor types. One such example involves the inhibition of epidermal growth factor receptor activity (7) .
The traditional concept of sensitivity or insensitivity of tumors and tumor cells to hormones is based on the presence or absence of steroid hormone (estradiol and progesterone) receptors. Using this traditional definition of hormone sensitivity, human astrocytic tumors are hormone insensitive, possessing very few or no estradiol receptors (8) . Progesterone receptors, sometimes present in high levels, are found to be nonfunctional (9) . It is likely that they are present in these tumors as a consequence of preoperative glucocorticoid treatment of the patients (9) . For example, administration of progesterone after induction of expression of progesterone receptors does not induce the appropriate hormonal response in uterine tissue (9) , thereby supporting the conclusion that the progesterone receptors expressed following glucocorticoid treatment are not functional. However, if the concept of hormone sensitivity is applied to other hormones and/or growth factors, it appears likely that astrocytic tumors might be hormone sensitive (10) (11) (12) (13) (14) . Gastrin represents one hormone to which astrocytic tumors may be sensitive.
Gastrin stimulates gastric acid secretion in the gut (75) but is also found in various normal and neoplastic tissues (15, 16) , where it may stimulate cell proliferation (17, 18) . It has also been hypothesized that gastrin is a neurotransmitter (79) because its expression has been demonstrated in numerous parts of the central and peripheral nervous systems of invertebrates (2021), fish (22) , and mammals (23) (24) (25) (26) (27) (28) . Since astrocytic tumors may develop in regions of the brain that may contain substantial amounts of gastrin, we decided to study the effect of gastrin on the proliferation of cells derived from these tumors. Indeed, the effect of gastrin on astrocytic brain tumors has not been actively investigated. Some of our preliminary results have already been reported (14) .
Gastrin and cholecystokinin (CCK) belong to the same family of gastrointestinal peptides. As with many other peptide hormones, they are synthesized as precursor molecules and undergo posttranslational processing, resulting in amidated products that are presumed to be the sole active forms (75). Nevertheless, post-translational intermediates of gastrin, such as glycine-extended gastrin (Ggly), are stored and secreted by several normal (25) and neoplastic (1629-31) tissues in concentrations sometimes higher than amidated gastrin. In addition, in some neoplastic tissues, including colon (32) and ovarian (76) carcinomas, the amount of G-gly is higher in malignant tissues than in normal or benign tissues.
Amidated gastrin and CCK peptides mediate their effects through at least two types of receptors (CCK receptors A and B) (35) . CCK receptor A molecules bind sulfated CCK peptides with high affinity and are found mostly in the gut, where their actions include stimulation of the exocrine pancreatic secretion, i.e., digestive proteolytic enzymes (75). CCK receptor B molecules are found predominantly in the central nervous system and stomach, and they are less specific in hormone binding than CCK receptor A molecules, since they bind both gastrin (sulfated or nonsulfated) and CCK (15) . Gastrin and/or CCK both possess growthmediating effects on different tissues (77,54,35).
Our goal was to characterize the influence of gastrin and gastrin and/or CCK antagonists (36) (37) (38) (39) on the proliferation in vitro of cells derived from human astrocytic tumors. Two biologic models were used as follows: 1) established cell lines growing as monolayers and 2) primary astrocytic tumors maintained as short-term ex vivo tumor tissue cell culture.
Materials and Methods

Compounds
Gastrin (pGlu-Gly-Pro-Trp-Leu-Glu-Glu-GluGlu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NHj) was purchased from Sigma Chemical Co. (St. Louis, MO) and was further purified by means of highpressure liquid chromatography on a Vydac column (C, 8> 300 A, 5 urn). The solvent was 0.1% trifluoroacetic acid in acetonitrile-water (3:1) and the gradient was from 33% to 55% over 15 minutes. Gastrin and/or CCK antagonists L-365,260 and L-364,718 were provided by P. Anderson (Merck & Co., Inc., West Point, PA) and compound CI-988 was provided by D. C. Horwell (Park Davis, Cambridge, U.K.). The CCK receptor A antagonist JMV 234 was synthesized in our laboratory, as previously described (39) . The structures and characteristics of these compounds have been detailed elsewhere (1536-39).
Quantitation of Gastrin Concentration in Culture Media
Gastrin concentrations in cell culture media were assessed at 4, 7, 11, and 15 days of culture. They were also quantified in a cell-free culture medium representing the control conditions (i.e., incubation of medium under identical conditions but in the absence of cells). For both the control cell-free incubations and the experimental cell culture incubations, the culture medium used was not supplemented with gastrin, but contains 10% fetal bovine serum. Each experiment was carried out in triplicate.
Gastrin concentrations in culture media were determined using a ' I-labeled gastrin radioimmunoassay kit from Incstar Corp. (Stillwater, MN). This assay is based on the competitive binding principles of radioimmunoassay, as described elsewhere (28) . A standard curve was drawn and the gastrin concentrations in the samples were interpolated from the standard curve. A 0-1000-pg/mL range of gastnn concentration was linearly covered by the standard curve. The gastrin antibody used is specific to gastnn-17, gastrin-34, and gastrin-13 (sulfated or nonsulfated) and has no cross-reactivity with either CCK or secretin.
Culture Media and Growth Conditions
Cells were cultured at 37 "C in sealed (air-tight) Falcon plastic dishes (Nunc, Inc., Gibco, Ghent, Belgium) containing Eagle's minimal essential medium (MEM; Life Technologies, Inc., [GIBCO BRL], Gaithersburg, MD) and supplemented with 10% fetal calf serum (FCS). All of the media were supplemented with a mixture of 0.6 mg/mL glutamine, 200 IU/mL penicillin, 200 IU/mL streptomycin, and 0.1 mg/mL gentamicin (all from Life Technologies, Inc.). The FCS was heat inactivated for 1 hour at 56 'C. In the experiments described below, the control condition signifies growth of cells in this culture medium in the absence of added gastnn or gastrin and/or CCK antagonists.
Cell Lines
Ten astrocytic tumor cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD). The ATCC numbers of these cell lines are HTB 14 (U87MG), HTB 17 (U373MG), CRL 1620 (A172), HTB 12 (SW1088), HTB138 (Hs683), HTB 13 (SW1783), HTB 148 (H4), CRL1690 (T98G), HTB15 (Ul 18MG), and HTB16 (U138MG).
The cell lines were incubated for 24 hours to ensure adequate plating prior to randomization to either experimental or control conditions. The cell lines were then incubated for an additional 72 hours in either the control condition or an experimental condition in which the culture medium was supplemented with either 0.01, 0.1, or 1 \iM of gastrin or 0.01, 0.1, and 1 \iM of one of the gastrin and/or CCK antagonists. 
In addition, we validated our results using two alternative techniques, genomic incorporation of tritiated thymidine (44) and direct cell counting (45) (data not shown).
Ex Vivo Tumor Tissue Cultures
Following surgical removal of astrocytic rumors from the patients, specimens were rinsed twice in MEM and immediately cut in half. One half was used for histopathologic diagnoses and the other half was immediately divided into pieces measuring approximately 2 mm . At least 20 pieces of 2 mm were available for each astrocytic rumor included in this study. Half of the randomly selected tumor pieces were used for control culture conditions and the other half were used for the gastrin-treated experimental conditions. For the experimental conditions, the culture media were supplemented with 10 nM gastrin The tumors were subsequently cultured for 48 hours in 30-mm (diameter) x 10-mm (height) Petri dishes (Nunc), each containing at least 10 and at most 15 tumor pieces and 3 mL of culture medium. Gastrin was dissolved in 0.2 mL of phosphate-buffered saline. An equal volume of this solvent was added to the control cultures. Only one concentration of gastrin (10 nM) was used because of the availability of the tumor material. This concentration was used because it was sufficient to cause statistically significant changes in the growth rates (compared with control conditions) of cells of several of the commercially available cell lines selected (Fig. 1) .
Assessment of cell proliferation in ex vivo tumor tissue cultures was performed by tritiated thymidine autoradiography. Details of this procedure are provided elsewhere (46) . Less than 1 hour elapsed between the surgical removal of the tumor and the setting up of the ex vivo tumor tissue culture. The cutting of the tumor into 2-mm pieces took an additional hour. One microcune per milliliter MEM of tritiated thymidine (Amersham, Little Chalfont, U.K.) was added to the culture media on four occasions (immediately after the addition of gastrin and then after 24, 36, and 47 hours of culture). After 48 hours of culture, samples were fixed in a solution containing 7 parts (by volume) 96% ethanol, 2.5 parts 40% formaldehyde, and 0.5 part glacial acetic acid. Following paraffin embedding, 6-Jim sections were prepared and dipped into K5 nuclear emulsion (Ilford, Sint Niklaas, Belgium), diluted with 1/3 (vol/vol) in double distilled water, air dried, and stored at 4 'C in a lightproof box for 3 weeks. After development with Dektol (Kodak, Vilvorde, Belgium) for 3 minutes and fixation in 25% sodium thiosulfate (E. Merck, Darmstadt, Federal Republic of Germany) (2x10 minutes), the autoradiographs were stained with hematoxylin (BDH Chemicals, Poole, U.K.) and eosin (BDH Chemicals) and mounted with DPX (BDH Chemicals). The labeling index corresponds to the percentage of cell nuclei covered by more than 10 (background) silver grains each and represents the percentage of cells in the S phase of the cell cycle.
Routine hematoxylin-eosin sections were prepared and analyzed for each of the tumor tissue 
Statistical Analysis
Results are presented as the mean ± standard error of the mean (SEM). Statistical comparisons of the data were made with the use of the one-way analysis of variance after checking the equality of variance by means of the Bartlett test and the normal distribution fitting of the data by means of the chisquared test. All of the P values resulted from twosided statistical tests. Each statistical analysis was performed with Statistica/Dos software (StatSoft, Tulsa, OK).
Results
Quantitation of Gastrin Concentration in Culture Media
After 4 days of incubation in mock culture conditions, the cell-free culture media contained approximately 14-pg/mL (6.7 x KT 6 \lM) gastrin. This basal (control) concentration of gastrin decreased significantly over time (P<.00l; day 15 versus day 4) (data not shown).
At 4 days of incubation, the media from culture of Hs683 and SW1783 cells contained concentrations of gastrin significantly (/ ) <.OO1 and P<.001, respectively) higher than in the control cell-free media at the same time point (data not shown). The concentration of gastrin in the culture media of the Hs683 and SW1783 cells gradually decreased during the following 11 days of culture.
For the remaining eight cell lines, the cell culture media exhibited a gastrin concentration significantly (P<.05 to P<.00l) lower than that measured in the cell-free control medium (data not shown).
Gastrin-Mediated Effects on the Growth of the Commercial Cell Lines
Gastrin used at 0.01, 0.1, and 1 \iM was found to significantly modify (P<.05 to P<.00l) the rate of cell proliferation in five of the 10 cell lines studied (Fig. 1) . These modifications represented either an increase (A 172, SW1088, and Hs683) or decrease (U373 and T98G) in cell line proliferation rates.
Since most peptides show a bellshaped curve on receptor-mediated functions, we report two full dose-response curves (range, 0.001-1000 nAf) with respect to the influence of gastrin on the proliferation of the Hs683 and A172 cell lines. Fig. 2 , A and C shows that such a gastrin-induced bell-shaped curve was observed for Hs683 cells. Bell-shaped response curves were also observed for both cell lines upon treatment with a range of concentrations of the putative antagonists (Fig. 2, B and D) . As reported in Table 1 , the lowest concentration tested in the present study was 10 nM, but in fact, many very potent peptide antagonists start to exhibit agonist activities at such a high concentration. Fig. 2 , B and D shows that this type of agonist activity in response to the CI-988 compound was greatest (and most statistically significant) in the A172 and Hs683 cell lines at concentrations of 1 and 10 \xM, respectively.
Gastrin-Mediated Effects on the Growth of the Ex Vivo Tumor Tissues
The influence of 10 nM gastrin on the cell proliferation of nine primary astrocytic tumors maintained as short-term ex vivo tumor tissue cultures was compared with the control condition. Compared with control (no added gastrin: control condition) cultures, this concentration of gastrin significantly increased (P<.05 to P<.00l) the proliferation rate of five cultures, significantly decreased (f<.01) it for one of the cultures, and had no statistically significant influence on the remaining three (Fig. 3) .
CCK Receptor Antagonist Effects on Commercial Cell Line Growth
Three concentrations were tested (0.01, 0.1, and 1 \iM) for each compound. No statistically significant (P>.05; chisquared test) dose-related effect was observed. Only the 10-nAf concentration is reported for the sake of clarity in Table 1 .
Relative to control cultures, compound L-365,260 (a CCK receptor B antagonist) significantly increased (P<.05 to P<.00l) cellular proliferation rates for seven of the 10 cell lines under study (Table 1) . Cell proliferation of the U87 cells was significantly (f<.01) decreased relative to control.
Compound CI-988 (another CCK receptor B antagonist) had a globally weak inhibitory influence in astrocytic tumor cell growth (Table 1) . Cell proliferation decreased in five of the 10 cell lines (A172, U373, U87, H4, and SW1783), increased in the U138 and T98G cell lines, and was unchanged in the remaining three cell lines (Ul 18, Hs683, and SW1O88).
The CCK receptor A antagonists L-364,718 and JMV 234 did not affect the rate of proliferation in seven of the 10 cell lines studied. Relative to control cultures, both compounds significantly decreased the rate of proliferation of U87 cells (P<.0\ in both cases) and H4 cells •Results are reported as mean percentages ± standard error of the mean compared with control condition, which arbitrarily equals 0% of cell proliferation. Percentages were calculated by comparison of the mean values of optical density measured in the MTT assays conducted on experimental and control cell cultures at the 96-hour incubation time point. Negative percentages reflect decreases in the relative rate of cellular proliferation. The statistical significance of the results is given in parentheses, n.s. = not significant.
(P<.01 in both cases). L-364,718 also decreased the proliferation rate of SW1783 cells (P<.0l), and JMV 234 increased the proliferation rate of A172 cells (Table 1) .
Discussion
Our data suggest that some astrocytic rumor cell lines are able to metabolize gastrin. Indeed, while gastrin progressively disappeared in the cell-free culture media, gastrin clearance in culture media increased significantly in the presence of eight of the 10 cell lines studied. The possibility remains that the apparent disappearance of gastrin from the media may well be a nonspecific protease effect unrelated to any specific receptor-mediated uptake system. Two cell lines secreted gastrin, since there was a significantly greater amount of gastrin than that observed in the control cell-free medium.
We then investigated whether gastrin might modify cell proliferation of neoplastic astrocytic cells. The data obtained on both in vitro biological models used in our study, i.e., monolayers (permanent cell lines) and ex vivo tumor tissues (freshly obtained tumor specimens cultured in vitro), show that gastrin modulated cell proliferation in a high proportion of astrocytic tumors. In both monolayer and ex vivo models, gastrin either increased or decreased proliferation significantly. Gastrin significantly modified the proliferation of astrocytic tumors to a similar extent in both models. The apparent inconsistencies in the data reported above regarding gastrin-induced inhibition versus stimulation of astrocytic tumor cell proliferation could be explained as follows. As reported by Bold et al. (48) , some peptide growth factors (including gastrin) regulate cell growth through multiple receptor-linked intracellular signal-transduction pathways, such as the cyclic adenosine monophosphate (cAMP) pathway. These authors (48) further reported that cAMP activates cAMP-dependent protein kinase A (PKA), either to stimulate or to inhibit cell growth. The proliferation of the cells can be either stimulated or inhibited because the effect of cAMP is determined by the presence of two isoforms of the regulatory (R) subunit of PKA. Activation of Ri a -type PKA leads to the stimulation of growth, whereas activation of the RHP-type inhibits cell growth. The predominance of one of the two isoforms in a given cell population dictates the gastrin-induced effect on cell growth, i.e., stimulation or inhibition (48) . The results of Bold et al. (48) relate to colorectal cell lines. We think that such a feature could also occur in astrocytic cell lines; therefore, we are conducting experiments to test this hypothesis in our laboratory.
The results obtained using CCK receptor B antagonists CI-988 (37) and L-365,260 (36) indicate that gastrin-mediated effects observed in astrocytic tumor cell lines might be induced in part through CCK receptor B. We confirm the antagonistic activity of CI-988; in five of the 10 astrocytic tumor cell lines studied, this compound antagonized the effect of gastrin.
In contrast to what was found for compound CI-988, our results suggest that compound L-365,260 acts as an agonist of CCK receptor B. In addition, we demonstrate that L-365,260 is more potent than gastrin in stimulating astrocytic rumor cell proliferation.
The selective CCK receptor A antagonists, L-364,718 (38) and JMV 234 (39), did not significantly influence the growth of the cell lines studied. However, the CCK receptor B is not the only gastrin receptor involved in growth regulation, since the new G-gly receptors possess mitogenic effects.
There is, in fact, no successful adjuvant therapy for astrocytic tumors, although hormone manipulation may offer a possibility in the future. We have demonstrated that luteinizing hormone-releasing hormone, epidermal growth factor, and transforming growth factor p\ respectively, significantly influenced the growth of several human astrocytic tumor cell lines (14) . In addition, it is possible to convert hormone-insensitive human colorectal (49) and murine mammary (50) cancers into hormone-sensitive cancers by hormone manipulation. Consequently, we are of the opinion that hormone stimulation might increase the hormone sensitivity in a given tumor. Given that undifferentiated cancers are thought to be more aggressive than differentiated cancers, it is conceivable that aggressive (hormone-insensitive) astrocytic tumors could be converted, at least partly, into less aggressive (hormone-sensitive) tumors by means of hormone manipulations. Although perhaps not providing cures, hormone therapy might induce the conversion of "undifferentiated" brain tumors into "differentiated" tumors, potentially increasing the time of survival for the patients.
In conclusion, our results suggest that gastrin (and potentially CCK) may play an important role in the proliferation of a substantial proportion of human astrocytic tumors. We are now testing several gastrin antagonists with the aim of obtaining the gastrin-specific inhibition of astrocytic tumor cell proliferation.
